Itraconazole Dosing Schedules (Common Clinical Use: Onychomycosis)
Itraconazole oral capsule dosing for onychomycosis should not be interchanged with other itraconazole formulations. [1]
Recommended Dosing Schedule (Onychomycosis)
Toenails with or without fingernail involvement
- 200 mg (2 capsules) once daily for 12 consecutive weeks. [1]
Fingernails only
- Pulse regimen: 200 mg (2 capsules) twice daily (400 mg/day) for 1 week.
- The pulse is separated by a 3-week period without itraconazole.
- 2 total pulses are used. [1]
Common Adverse Effects
Most common adverse reactions (onychomycosis clinical trials)
- Upper respiratory tract infections. [2]
- Increased hepatic enzymes. [2]
- Hypoacusis. [2]
- Headache. [2]
- Abdominal pain. [2]
- Diarrhea. [2]
- Nausea. [2]
- Fatigue. [2]
- Arrhythmia. [2]
- Cough. [2]
- Sore throat. [2]
- Back pain. [2]
Additional adverse effects with clinical relevance
- Serious hepatotoxicity is possible, including liver failure and death. [2]
- Congestive heart failure and other cardiac events are possible, and itraconazole is contraindicated for onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure or a history of congestive heart failure. [1]
- Peripheral edema and pulmonary edema have been reported. [2]
- Hypokalemia has been reported in systemic infection trials. [2]
- Pseudoaldosteronism has been reported in post-marketing data, with hypertension or worsening of hypertension and abnormal laboratory findings. [3]
- Anaphylaxis and allergic reactions have been reported. [1]
Necessary Monitoring
Cardiac monitoring
- Development of signs or symptoms of congestive heart failure requires discontinuation. [1]
- Patients with risk factors for congestive heart failure require monitoring for signs and symptoms during treatment. [1]
Hepatic monitoring
- Liver function monitoring should be considered in all patients receiving itraconazole. [3]
- If clinical signs or symptoms consistent with liver disease develop, treatment should be discontinued and liver function testing performed. [3]
Laboratory monitoring for electrolyte and blood pressure effects
- Blood pressure and potassium levels require monitoring due to reported pseudoaldosteronism and associated hypokalemia. [3]
Drug interaction and arrhythmia risk monitoring
- Concomitant use with interacting drugs can increase plasma concentrations and can be associated with serious cardiovascular events, including QT prolongation and torsades de pointes, with certain interacting agents. [2]
- Therapy should be avoided with contraindicated interacting drugs listed in prescribing information due to serious cardiovascular risk. [2]
Therapeutic drug monitoring (TDM)
- Routine TDM is recommended for prophylaxis or treatment doses of itraconazole capsules (Sporanox) in published drug-interaction/PK guidance describing the high variability in capsule bioavailability. [4]
- Routine TDM should be considered more strongly in immunosuppressed patients or patients with hematologic malignancies when using itraconazole capsules, based on increased risk of subtherapeutic exposure. [4]
Administration-Related Considerations Affecting Exposure (Monitoring-Relevant)
- Itraconazole oral capsules should be taken with a full meal to ensure maximum absorption. [1]
Common Pitfalls to Avoid
- Switching between itraconazole oral solution and oral capsule formulations should be avoided due to non-equivalence of exposure and effectiveness for specific indications. [1]
- Using itraconazole capsules for onychomycosis in patients with congestive heart failure or a history of congestive heart failure should be avoided because this contraindication is based on boxed warning safety concerns. [1]
- Overlooking interactions that increase itraconazole exposure or the exposure of affected co-medications should be avoided due to serious cardiovascular toxicity risk described with certain CYP3A4-related combinations. [2]
- Omitting liver function monitoring should be avoided because serious hepatotoxicity has been observed, including cases developing within the first week of treatment. [3]
Dosing Schedule and Monitoring Reference Sources
- Onychomycosis dosing schedules, contraindications, and pulse regimen details for itraconazole capsules are provided in prescribing information. [1]
- Common adverse reactions and major warnings related to cardiac and hepatic toxicity are provided in prescribing information. [2]
- Liver function monitoring, QT/cardiovascular interaction warnings, and pseudoaldosteronism electrolyte monitoring are described in prescribing information. [3]
- Therapeutic drug monitoring considerations based on itraconazole capsule bioavailability variability are described in clinical pharmacy guidance. [4]